Fourth-Generation Fluoroquinolone Penetration into the Aqueous Humor in Humans

Ophthalmology

Volumn 113, Issue 6, 2006, Pages 955-959

  McCulley, J P ^a   Caudle, D ^a   Aronowicz, J D ^a   Shine, W E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; CALCULATION; CATARACT EXTRACTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG PENETRATION; EYE INFECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LENS IMPLANT; LIPOPHILICITY; MALE; PH MEASUREMENT; PHACOEMULSIFICATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SOLUBILITY; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, TOPICAL; AGED; ANTI-BACTERIAL AGENTS; AQUEOUS HUMOR; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; FEMALE; FLUOROQUINOLONES; HUMANS; LENS IMPLANTATION, INTRAOCULAR; MALE; MICROBIAL SENSITIVITY TESTS; OPHTHALMIC SOLUTIONS; PHACOEMULSIFICATION; PROSPECTIVE STUDIES; QUINOLINES;

EID: 33646925640     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.01.061     Document Type: Article

References (32)

1. Mather R., Karenchak L.M., Romanowski E.Q., and Kowalski R.P. Fourth generation fluoroquinolones. new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 133 (2002) 463-466
2. Liang H., Kays M.B., and Sowinski K.M. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography. application to levofloxacin determination in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 772 (2002) 53-63
3. Mather R., Stewart J.M., Prabriputaloong T., et al. The effect of cataract surgery on ocular levels of topical moxifloxacin. Am J Ophthalmol 138 (2004) 554-559
4. Arnold P.P. Cataract and refractive surgery-the other side of the pond (2005). http://www.bbriefings.com/pdf/952/Arnold.pdf Available at: http://www.bbriefings.com/pdf/952/Arnold.pdf. Accessed January 18.
5. Colleaux K.M., and Hamilton W.K. Effect of prophylactic antibiotics and incision type on the incidence of endophthalmitis after cataract surgery. Can J Ophthalmol 35 (2000) 373-378
6. Karp C.L., Tuli S.S., Yoo S.H., et al. Infectious keratitis after LASIK. Ophthalmology 110 (2003) 503-510
7. Nagaki Y., Hayasaka S., Kadoi C., et al. Bacterial endophthalmitis alter small-incision cataract surgery. effect of incision placement and intraocular lens type. J Cataract Refract Surg 29 (2003) 20-26
8. Bratzler D.W., Houck P.M., and Surgical Infection Prevention Guidelines Writers Workgroup. Antimicrobial prophylaxis for surgery. an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 38 (2004) 1706-1715
9. Leaming D.V. Practice styles and preferences of ASCRS member. 2000 survey. J Cataract Refract Surg 27 (2001) 948-955
10. Stonecipher K.G., Parmley V.C., Jensen H., and Rowsey J.J. Infectious endophthalmitis following sutureless cataract surgery. Arch Ophthalmol 109 (1991) 1562-1563
11. McDonnell P.J., Taban M., Sarayba M., et al. Dynamic morphology of clear corneal cataract incisions. Ophthalmology 110 (2003) 2342-2348
12. Shingleton B.J., Wadhwani R.A., O'Donoghue M.W., et al. Evaluation of intraocular pressure in the immediate period after phacoemulsification. J Cataract Refract Surg 27 (2001) 524-527
13. McCulley J.P. Low acute endophthalmitis rate. possible explanations [letter]. J Cataract Refract Surg 31 (2005) 1074-1075
14. Mah F.S. Fourth-generation fluoroquinolones. new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol 15 (2004) 316-320
15. Han D.P., Wisniewski S.R., Wilson L.A., et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 122 (1996) 1-17
16. Alfonso E., and Crider J. Ophthalmic infections and their anti-infective challenges. Surv Ophthalmol 50 suppl (2005) S1-S6
17. Abshire R., Cockrum P., Crider J., and Schlech B. Topical antibacterial therapy for mycobacterial keratitis. potential for surgical prophylaxis and treatment. Clin Ther 26 (2004) 191-196
18. Aliprandis E., Ciralsky J., Lai H., et al. Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits. Cornea 24 (2005) 201-205
19. Durrie D.S., and Trattler W. A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. J Ocular Pharm Ther 21 (2005) 236-241
20. Kim D.H., Stark W.J., and O'Brien T.P. Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery. Cur Med Res Opin 21 (2005) 93-94
21. Kovoor T.A., Kim A.S., McCulley J.P., et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens 30 (2004) 90-94
22. Kowalski R.P., Dhaliwal D.K., Karenchak L.M., et al. Gatifloxacin and moxifloxacin. an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 136 (2003) 500-505
23. Kowalski R.P., Romanowski E.G., Mah F.S., et al. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol 138 (2004) 33-37
24. Kim D.H., Stark W.J., O'Brien T.P., and Dick J.D. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 112 (2005) 1992-1996
25. Katz H.R., Masket S., Lane S.S., et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea 24 (2005) 955-958
26. Solomon R., Donnenfeld E.D., Perry H.D., et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 112 (2005) 466-469
27. Price Jr. F.W., Dobbins K., and Zeh W. Penetration of topically administered ofloxacin and trimethoprim into aqueous humor. J Ocular Pharmacol Ther 18 (2002) 445-453
28. Bucci Jr. F.A. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. Am J Ophthalmol 137 (2004) 308-312
29. Liu W., Liu Q.F., Perkins R., et al. Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits. physicochemical properties that regulate penetration of quinolone antimicrobials. Antimicrob Agents Chemother 42 (1998) 1417-1423
30. Schentag J.J. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy. moxifloxacin and Streptococcus pneumoniae. J Chemother 14 suppl (2002) 13-21
31. Metzler K., Hansen G.M., Hedlin P., et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 24 (2004) 161-167
32. Neu H.C., and Ellner P.D. The inhibitory quotient. Bull N Y Acad Med 59 (1983) 430-442